Law360, New York (August 10, 2012, 4:04 PM ET) -- Roche Holding AG’s blockbuster medicine Lucentis on Friday became the first pharmaceutical approved by the U.S. Food and Drug Administration for treatment of diabetic macular edema, an eye condition affecting more than half a million Americans.
The drug is marketed in the U.S. by Roche unit Genentech Inc., which says 560,000 diabetics suffer from the eye disease and that 75,000 new cases are diagnosed each year. Shipments are set to begin within days, likely boosting already strong sales of Lucentis, which racked up domestic revenues of...
Roche Blockbuster Lucentis Gets FDA Nod For Broader Use
To view the full article, take a free trial now.
